Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2003 September;28(3) > Minerva Endocrinologica 2003 September;28(3):223-32

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118


eTOC

 

REVIEWS  


Minerva Endocrinologica 2003 September;28(3):223-32

language: English

Glucocorticoids in the medical management of Graves' ophthalmopathy

Hart R. H., Perros P.


PDF  


Graves' ophthalmopathy (GO) is a challenging disease that poses therapeutic dilemmas for endocrinologists and ophthalmologists. Progress in medical therapy has been slow. Numerous new treatments have been reported to have a beneficial effect. However, current evidence indicates that glucocorticoids (GC) represent the only class of drug therapy which either in isolation or combined with other therapies has an unequivocal role in the routine clinical management of patients with GO. Recent advances include better definition of factors predictive of response to treatment and the formulation of specific GC regimens that combine high efficacy with a low risk of unwanted side-effects.

top of page

Publication History

Cite this article as

Corresponding author e-mail